GLUE
Monte Rosa Therapeutics Inc

1,442
Mkt Cap
$1.25B
Volume
5.47M
52W High
$25.77
52W Low
$3.50
PE Ratio
-25.33
GLUE Fundamentals
Price
$15.63
Prev Close
$16.06
Open
$16.04
50D MA
$19.78
Beta
1.52
Avg. Volume
1.03M
EPS (Annual)
-$0.465
P/B
4.40
Rev/Employee
$824,480.00
$964.64
Loading...
Loading...
News
all
press releases
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen cut shares of Monte Rosa Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) released its earnings results on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·4d ago
News Placeholder
Wells Fargo & Company Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price
Wells Fargo & Company dropped their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an "overweight" rating on the stock in a report on Wednesday...
MarketBeat·4d ago
News Placeholder
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00
Guggenheim lowered their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a "buy" rating for the company in a research note on Wednesday...
MarketBeat·4d ago
News Placeholder
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -17.02% and -72.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
Agenus (AGEN) delivered earnings and revenue surprises of +144.27% and +17.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·10d ago
News Placeholder
Monte Rosa Therapeutics (GLUE) to Release Quarterly Earnings on Thursday
Monte Rosa Therapeutics (NASDAQ:GLUE) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...
MarketBeat·10d ago
News Placeholder
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -28.67% and -41.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) CEO Markus Warmuth sold 5,466 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an...
MarketBeat·18d ago
<
1
2
...
>

Latest GLUE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.